P. Anderlini

N. Ueno, R. Champlin, L. Miller, 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide

K. Rezvani, D. Marin, E. Shpall, 2021, Transplantation and Cellular Therapy.

Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation

E. Shpall, U. Popat, M. Qazilbash, 2007, Leukemia.

Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors.

R. Champlin, P. Anderlini, M. Körbling, 2001, Blood.

Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas.

E. Shpall, P. Mclaughlin, J. Manning, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma

U. Popat, M. Qazilbash, R. Champlin, 2011, Bone Marrow Transplantation.

Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015, British journal of haematology.

Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial.

K. Rezvani, D. Marin, E. Shpall, 2021, Transplantation and cellular therapy.

Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma.

S. Parmar, E. Shpall, Y. Nieto, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality.

P. Mclaughlin, F. Cabanillas, F. Cabanillas, 2001, Blood.

Disease Susceptibility to Graft-vs-Malignancy Effects

N. Ueno, R. Champlin, J. Mcmannis, 2017 .

Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation.

K. Cleary, D. Couriel, R. Champlin, 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors.

G. Hortobagyi, E. Jonasch, D. Booser, 2003, Blood.

Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation

N. Ueno, S. Kornblau, R. Champlin, 2001, Bone Marrow Transplantation.

Allogeneic hematopoietic transplantation for indolent lymphomas: improved outcome with non-myeloablative versus high dose chemotherapy (HDCT) regimens

N. Ueno, F. Cabanillas, A. Younes, 2000 .

Age over Fifty-Five Years at Diagnosis Increases Risk of Second Malignancies after Autologous Transplantation for Patients with Hodgkin Lymphoma.

Y. Nieto, U. Popat, M. Qazilbash, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Hematopoietic stem-cell transplantation for Hodgkin's disease (HD): current status.

P. Anderlini, 2002, Cytotherapy.

Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center

N. Ueno, B. Andersson, Y. Nieto, 2012, Leukemia & lymphoma.

High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies.

P. Thall, S. Parmar, E. Shpall, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B‐cell lymphoma treated with autologous stem cell transplantation

H. Macapinlac, U. Popat, M. Qazilbash, 2008, British journal of haematology.

Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial.

Michael L. Wang, Y. Nieto, U. Popat, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

An asterisk indicates reviewers who have evaluated three or more manuscripts in 2012.

David Ball, Ash A. Alizadeh, David A. August, 2013 .

Severe hepatitis C reactivation as an early complication of hematopoietic cell transplantation

Y. Nieto, H. Torres, B. Blechacz, 2017, Bone Marrow Transplantation.

Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield.

J. Wingard, T. Spitzer, B. Shaw, 2020, Blood advances.

Allogeneic stem cell transplantation for chronic myeloid leukemia resistant to tyrosine kinase inhibitors.

E. Jabbour, B. Andersson, R. Champlin, 2011, Clinical lymphoma, myeloma & leukemia.

Allogeneic Stem Cell Transplantation for CML Resistant to Tyrosine Kinase Inhibitors

E. Jabbour, P. Anderlini, P. Kebriaei, 2011 .

Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era.

H. Kantarjian, E. Shpall, J. Cortes, 2009, Clinical lymphoma & myeloma.

High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome.

B. Andersson, U. Popat, M. de Lima, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results

E. Shpall, A. Younes, Y. Nieto, 2012, Leukemia & lymphoma.

Haploidentical vs Matched Unrelated vs Matched Sibling Donor HCT with Post-Transplantation Cyclophosphamide.

K. Rezvani, D. Marin, E. Shpall, 2022, Transplantation and cellular therapy.

Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia.

H. Putter, H. Deeg, H. Einsele, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic Hematopoietic Cell Transplantation in Patients aged 50 years or older with Severe Aplastic Anemia

H. Deeg, H. Einsele, M. Hallek, 2019 .

Sixty as the new forty: considerations on older related stem cell donors

P. Anderlini, 2017, Bone Marrow Transplantation.

Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma.

P. Mclaughlin, F. Cabanillas, A. Younes, 1999, Leukemia & lymphoma.

Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial

Y. Oki, L. Medeiros, A. Younes, 2016, Leukemia & lymphoma.

Vorinostat combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-term Study Outcomes.

P. Thall, D. Marin, E. Shpall, 2022, Transplantation and cellular therapy.

Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges.

R. Champlin, P. Anderlini, 2008, Blood.

Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant.

Michael L. Wang, U. Popat, M. Qazilbash, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Primary plasma cell leukemia: morphologic, immunophenotypic, and cytogenetic features of 4 cases treated with chemotherapy and stem cell transplantation.

L. Medeiros, C. Bueso-Ramos, R. Champlin, 2006, Annals of diagnostic pathology.

Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals.

R. Champlin, P. Anderlini, M. Körbling, 1996, Blood.

Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type

E. Shpall, U. Popat, J. Tarrand, 2010, Haematologica.

Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer.

G. Hortobagyi, N. Ueno, B. Andersson, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant

S. Parmar, U. Popat, Q. Bashir, 2012, Leukemia & lymphoma.

Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD.

E. Shpall, B. Andersson, D. Couriel, 2006, Blood.

Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation.

M. Andreeff, P. Fox, K. Rezvani, 2015, Blood.

Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience

P. Anderlini, M. Körbling, R. Champlin, 1999, Transfusion.

Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1.

N. Ueno, K. Cleary, K. van Besien, 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Severe thrombosis and acute thrombocytopenia in a cancer patient

S. Yeung, P. Anderlini, V. Afshar-Kharghan, 2010, American journal of hematology.

Acanthamoeba meningoencephalitis after bone marrow transplantation.

M. Andreeff, A. Deisseroth, P. Anderlini, 1994, Bone marrow transplantation.

Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma.

L. Medeiros, C. Tam, U. Popat, 2009, Blood.

Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies

E. Shpall, S. Kornblau, M. Qazilbash, 2007, Bone Marrow Transplantation.

Recombinant human thrombopoietin augments mobilization of peripheral blood progenitor cells for autologous transplantation.

J. Fay, Dennie V. Jones, J. Lynch, 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Age over 55 Years at Diagnosis Increases Risk of Second Malignancies after Auto-Transplantation for Hodgkin's Lymphoma Patients

E. Shpall, Y. Nieto, U. Popat, 2015 .

Clinical toxicity and laboratory effects of granulocyte‐colony‐ stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures

R. Champlin, P. Miller, P. Anderlini, 1996, Transfusion.

Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease.

M. Andreeff, A. Deisseroth, K. van Besien, 1995, Blood.

Respiratory syncytial virus infections in autologous blood and marrow transplant recipients with breast cancer: combination therapy with aerosolized ribavirin and parenteral immunoglobulins

D. Kontoyiannis, J. Tarrand, K. Rolston, 2001, Bone Marrow Transplantation.

Treatment of myelogenous leukemia: current status and investigational options.

H. Kantarjian, M. Talpaz, S. O'brien, 1996, Blood.

Allogeneic blood stem cell transplantation in advanced hematologic cancers

P. Thall, A. Deisseroth, K. Cleary, 1997, Bone Marrow Transplantation.

Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma

K. Rezvani, D. Marin, S. Parmar, 2016, Leukemia & lymphoma.

High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma.

B. Andersson, L. Medeiros, A. Younes, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

transplantation strategy in mantle cell lymphoma Mature results of the M. D. Anderson Cancer Center risk-adapted

L. Medeiros, C. Tam, U. Popat, 2013 .

Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma.

Y. Oki, E. Shpall, A. Younes, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Treatment of Chronic Myelogenous Leukemia: Current Status and Investigational Options

H. Kantarjian, M. Talpaz, S. O'brien, 1996 .

Use of Filgrastim for Stem Cell Mobilisation and Transplantation in High-Dose Cancer Chemotherapy

R. Champlin, P. Anderlini, 2002, Drugs.

Debulking blood stem cell collections by density gradient centrifugation in a closed-vessel system.

P. van Vlasselaer, A. Gee, R. Champlin, 1999, Cytotherapy.

Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy.

N. Ueno, S. Kornblau, R. Champlin, 2000, British journal of haematology.

Fixed‐dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma

E. Shpall, U. Popat, M. Qazilbash, 2006, British journal of haematology.

Leukapheresis Reduces Early Mortality in Patients with Acute Myeloid Leukemia with High White Cell Counts But Does Not Improve Long Term Survival

Yu Shen, H. Kantarjian, S. Pierce, 2001, Leukemia & lymphoma.

Acute myeloid leukemia-type chemotherapy for myelodysplasia.

H. Kantarjian, P. Anderlini, S. Pierce, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes.

E. Estey, H. Kantarjian, M. Keating, 1996, Leukemia.

Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Survival for Patients with Chronic Myelomonocytic Leukemia

K. Rezvani, D. Marin, H. Kantarjian, 2015 .

Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study

H. Kantarjian, F. Ravandi, S. Giralt, 2001, Bone Marrow Transplantation.

Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphoma: The M.D. Anderson Cancer Center Experience,

B. Andersson, U. Popat, Q. Bashir, 2011 .

Non-Myeloablative Allogeneic Stem Cell Transplantation (NMT) Overcomes the Adverse Effects of Treatment Resistance and High Beta-2-Microglobulin in Patients with Mantle Cell Lymphoma (MCL): An Analysis of 123 Transplantations at the MD Anderson Cancer Center.

Michael L. Wang, C. Tam, U. Popat, 2007 .

Reduced intensity conditioning for allogeneic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: where do we stand?

R. Champlin, P. Anderlini, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A Phase I/II Trial of Plerixafor/G-CSF Combined with IV Bu/Flu Conditioning Regimen In AML/MDS Patients Undergoing Allogenic Stem Cell Transplantation

P. Thall, M. Konopleva, M. Andreeff, 2010 .

Stem Cell Transplantation with 90yttrium Ibritumomab Tiuxetan(90YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies.

D. Podoloff, T. Manshouri, P. Mclaughlin, 2009 .

Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program.

J. Klein, M. Horowitz, B. Logan, 2009, Blood.

and graft-versus-host disease 1dim) and lymphoid subsets, and possible predictors of engraftment of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy- Allogeneic blood stem cell transplantation: peripheralization and yield

M. Andreeff, P. Miller, P. Anderlini, 2010 .

Mobilization kinetics of CD34+/Thy‐1dim progenitor cells during recombinant human granulocyte‐colony‐stimulating factor administration in normal donors

R. Champlin, P. Anderlini, Y. Huh, 1997, Transfusion.

Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan.

U. Popat, M. Qazilbash, D. Couriel, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Chronic graft-versus-host disease after allogeneic blood stem cell transplantation.

K. Cleary, K. van Besien, I. Braunschweig, 2001, Blood.

Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010.

H. Deeg, J. Tolar, S. Savage, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Poor hematopoietic stem cell mobilizers: A single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma

U. Popat, M. Qazilbash, A. Alousi, 2009, American journal of hematology.

Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen

M. Aljurf, J. Passweg, A. Bacigalupo, 2009, Haematologica.

Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose.

J. Klein, M. Horowitz, B. Logan, 2009, Blood.

Race and ethnicity influences collection of granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells from unrelated donors, a Center for International Blood and Marrow Transplant Research analysis.

J. Wingard, B. Shaw, H. Lazarus, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Factors predicting complete remission and subsequent disease-free survival after a second course of induction therapy in patients with acute myelogenous leukemia resistant to the first.

E. Estey, H. Kantarjian, E. Freireich, 1996, Leukemia.

Marginal Keratitis Associated With Administration of Filgrastim and Sargramostim in a Healthy Peripheral Blood Progenitor Cell Donor

B. Esmaeli, Stella K. Kim, P. Anderlini, 2002, Cornea.

Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus.

A. Deisseroth, K. Cleary, K. van Besien, 1996, Transplantation.

Effects and safety of granulocyte colony-stimulating factor in healthy volunteers

P. Anderlini, 2009, Current opinion in hematology.

Transient neutropenia in normal donors after G‐CSF mobilization and stem cell apheresis

P. Anderlini, M. Körbling, D. Przepiorka, 1996, British journal of haematology.

Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma.

N. Ueno, K. Cleary, B. Andersson, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma

B. Andersson, R. Champlin, A. Shimoni, 2001, Bone Marrow Transplantation.

Fludarabine with Myeloablative Timed-Sequential Busulfan in Older Patients: Results of a Randomized Phase II Clinical Trial

K. Rezvani, D. Marin, S. Parmar, 2019 .

Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial.

K. Rezvani, D. Marin, S. Parmar, 2018, The Lancet. Haematology.

Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure.

H. Deeg, J. Wagner, R. Gale, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study.

D. Berry, J. Wathen, S. Parmar, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment.

E. Shpall, Caimiao Wei, U. Popat, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Long‐term follow‐up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T‐cell chimerism is associated with high relapse risk and inferior survival

F. Stingo, Z. Estrov, K. Rezvani, 2017, British journal of haematology.

Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease

P. Mclaughlin, J. Manning, F. Cabanillas, 2000, Bone Marrow Transplantation.

Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim

R. Champlin, P. Anderlini, M. Körbling, 1997, Transfusion.

Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma

N. Ueno, A. Anagnostopoulos, D. Weber, 2002, Bone Marrow Transplantation.

Allogeneic peripheral blood stem cell collection as of 2008.

P. Anderlini, B. Rhodes, 2008, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is widely used in normal donors for collection of peripheral blood progenitor cells (PBPCs) for allogeneic transplantation and granulocytes for transfusion. The spectrum of its biologic and molecular activities in normal individuals

R. Champlin, P. Anderlini, 2007 .

Long-term follow-up of normal peripheral blood progenitor cell donors treated with filgrastim: no evidence of increased risk of leukemia development

P. Anderlini, M. Körbling, R. Champlin, 2002, Bone Marrow Transplantation.

A comparative study of once‐daily versus twice‐daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors

R. Champlin, P. Anderlini, M. Körbling, 2000, British journal of haematology.

Collection of peripheral blood stem cells from normal donors 60 years of age or older

R. Champlin, P. Anderlini, M. Körbling, 1997, British journal of haematology.

Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis

M. Andreeff, R. Champlin, J. Mcmannis, 2001, Journal of clinical apheresis.

Duration of filgrastim mobilization and apheresis yield of CD34+ progenitor cells and lymphoid subsets in normal donors for allogeneic transplantation

R. Champlin, P. Miller, P. Anderlini, 1996, British journal of haematology.

Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less.

J. Szer, D. Stroncek, J. Liesveld, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Peripheral blood stem cell apheresis in normal donors: feasibility and yield of second collections

R. Champlin, P. Anderlini, D. Przepiorka, 1997, British journal of haematology.

Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma

Michael L. Wang, S. Parmar, R. Orlowski, 2012, American journal of hematology.

Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma

Michael L. Wang, S. Parmar, R. Orlowski, 2012, Leukemia & lymphoma.

Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases

N. Schmitz, R. Champlin, J. Rizzo, 2001, Bone Marrow Transplantation.

Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease.

K. Rezvani, D. Marin, E. Shpall, 2021, Transplantation and cellular therapy.

Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation

E. Jabbour, D. Couriel, R. Champlin, 2007, Bone Marrow Transplantation.

Syngeneic blood stem cell transplantation for infectious mononucleosis‐related aplastic anaemia

R. Champlin, P. Anderlini, M. Körbling, 1999, British journal of haematology.

Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy.

N. Ueno, S. Kornblau, F. Marini, 1999, Hematology/oncology clinics of North America.

Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis.

B. Andersson, Y. Nieto, U. Popat, 2009 .

Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Biology and current indications.

N. Ueno, R. Champlin, M. de Lima, 2003, Oncology.

E. Shpall, B. Andersson, U. Popat, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL

D. Marin, T. Kadia, E. Jabbour, 2017, Bone Marrow Transplantation.

Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies

K. Rezvani, D. Marin, E. Shpall, 2022, Frontiers in Immunology.

Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results.

J. Varni, W. Tse, M. Horowitz, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study.

P. Hari, J. Varni, W. Tse, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma

Yuan Ji, Paolo Anderlini, A. Younes, 2011, British journal of haematology.

Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study.

P. Thall, S. Parmar, R. Champlin, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Epstein–Barr virus-associated, CD20− polyclonal lymphoproliferative disorder after matched unrelated donor marrow transplantation

C. Bueso-Ramos, P. Anderlini, R. Champlin, 2004, Bone Marrow Transplantation.

Shorter Interdonation Interval Contributes to Lower Cell Counts in Subsequent Stem Cell Donations.

D. Stroncek, B. Shaw, G. Switzer, 2021, Transplantation and cellular therapy.

Mobilized PBPC concentrates: a maturing blood component

D. Stroncek, P. Anderlini, D. Stroncek, 2001, Transfusion.

A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS

P. Thall, D. Marin, E. Shpall, 2019, Blood.

Age at diagnosis does not adversely affect outcome in patients with Hodgkin's Disease (HD) after autologous transplantation.

U. Popat, M. Qazilbash, A. Alousi, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response

N. Ueno, D. Couriel, R. Champlin, 2004, Bone Marrow Transplantation.

Practice patterns for evaluation, consent, and care of related donors and recipients at hematopoietic cell transplantation centers in the United States.

D. Stroncek, M. Pulsipher, S. Leitman, 2010, Blood.

Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.

E. Estey, H. Kantarjian, S. Kornblau, 1997, Blood.

A Long-Term Survivor of Disseminated Aspergillus and Mucorales Infection: An Instructive Case

G. Fuller, D. Kontoyiannis, P. Anderlini, 2014, Mycopathologia.

Scleritis as the initial clinical manifestation of graft-versus-host disease after allogenic bone marrow transplantation.

B. Esmaeli, P. Anderlini, R. Y. Kim, 2002, American journal of ophthalmology.

Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies

E. Shpall, L. Lekakis, D. Couriel, 2006, Bone Marrow Transplantation.

Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation.

P. Thall, E. Estey, N. Ueno, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Nosocomial Outbreak Caused by a Multiresistant Clone of Acinetobacter baumannii: Results of the Case- Control and Molecular Epidemiologic Investigations

L. Armitige, A. Wanger, P. Anderlini, 1995, Infection Control & Hospital Epidemiology.

Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR

S. Parmar, B. Andersson, Y. Nieto, 2012, Bone Marrow Transplantation.

J. Vose, P. Hari, R. Gale, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia

E. Estey, M. Andreeff, N. Ueno, 2001, American journal of hematology.

Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia.

P. Thall, B. Andersson, H. Tran, 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Overcoming the Negative Impact of Age Using Fludarabine-Based Conditioning Regimens for HLA-Identical Sibling HSCT in Patients with Severe Aplastic Anemia (SAA): A Study from the EBMT-SAA Working Party.

D. Blaise, J. Passweg, A. Bacigalupo, 2006 .

Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes.

H. Kantarjian, E. Shpall, F. Ravandi, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic blood stem cell transplantation

R. Champlin, P. Anderlini, D. Przepiorka, 1997 .

Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.

P. Thall, M. Andreeff, N. Ueno, 2001, Blood.

Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma.

Michael L. Wang, U. Popat, M. Qazilbash, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.

N. Ueno, B. Andersson, M. Keating, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.

A. Alousi, R. Champlin, M. de Lima, 2007, Blood.

West Nile encephalitis in 2 hematopoietic stem cell transplant recipients: case series and literature review.

G. Fuller, N. Leeds, D. Hong, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes.

Y. Oki, F. Turturro, Y. Nieto, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma

J. Cox, F. Cabanillas, B. Andersson, 2004, Bone Marrow Transplantation.

Outcomes of Haploidentical Stem Cell Transplantation for Lymphoma with Melphalan-Based Conditioning.

R. Champlin, C. Tomuleasa, Saira S Ahmed, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning in allogeneic stem cell transplantation

P. Thall, M. Konopleva, M. Andreeff, 2015, Bone Marrow Transplantation.

Double epigenetic modulation of high‐dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor‐risk relapsed lymphoma

P. Thall, Y. Oki, E. Shpall, 2016, Cancer.

Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.

P. Thall, Y. Oki, E. Shpall, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.

S. Parmar, E. Shpall, B. Valdez, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome

P. Thall, J. D. Cook, E. Shpall, 2008, Leukemia.

Tumor necrosis factor- (cid:1) blockade for the treatment of acute GVHD

B. Andersson, D. Kontoyiannis, D. Couriel, 2004 .

Haploidentical Transplantation for Advanced Hematologic Malignancies Using Melphalan-Based Conditioning – Mature Results from a Single Center

E. Shpall, U. Popat, Q. Bashir, 2014 .

Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels.

E. Leifer, H. Deeg, J. Tolar, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Fludarabine, cyclophosphamide, and antithymocyte globulin for matched related and unrelated allogeneic stem cell transplant in severe aplastic anemia

E. Shpall, U. Popat, M. Qazilbash, 2011, Leukemia & lymphoma.

Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation.

N. Ueno, K. Cleary, B. Andersson, 1999, Blood.

Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.

Michael L. Wang, E. Shpall, B. Andersson, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.

B. Andersson, D. Kontoyiannis, D. Couriel, 2004, Blood.

Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program.

J. Wingard, D. Stroncek, B. Shaw, 2013, Blood.

Allogeneic peripheral blood stem cell transplantation using normal patient-related pediatric donors.

B. Andersson, K. van Besien, P. Miller, 1996, Bone marrow transplantation.

Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter?

P. Anderlini, M. Körbling, M Körbling, 2001, Blood.

European Group for Blood and Marrow Transplantation Centers with FACT-JACIE Accreditation Have Significantly Better Compliance with Related Donor Care Standards.

M. Norkin, B. Shaw, G. Switzer, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

J. Wingard, M. Bishop, G. Switzer, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study.

E. Leifer, H. Deeg, M. Horowitz, 2015, The Lancet. Haematology.

Steroid-Refractory Acute GVHD: Predictors and Outcomes

E. Shpall, B. Andersson, M. Qazilbash, 2011, Advances in hematology.

High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer

J. Wharton, D. Gershenson, S. Giralt, 2000, Bone Marrow Transplantation.

Blood stem cell procurement: donor safety issues.

R. Champlin, P. Anderlini, M. Körbling, 1998, Bone marrow transplantation.

Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation

K. Cleary, R. Champlin, I. Braunschweig, 1999, Bone Marrow Transplantation.

Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia

H. Deeg, M. Ayas, M. Pulsipher, 2017, Haematologica.

Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30(+) Lymphoma Patients Who Received Multiple Prior Lines of Treatment.

Y. Nieto, U. Popat, S. Gerson, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Clinical outcomes in adult patients with aplastic anemia: A single institution experience

S. Parmar, H. Kantarjian, G. Garcia-Manero, 2017, American journal of hematology.

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.

P. Mclaughlin, N. Ueno, L. Medeiros, 2008, Blood.

Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia.

M. Andreeff, H. Kantarjian, R. Benjamin, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia.

K. Rezvani, D. Marin, H. Kantarjian, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time.

M. Norkin, J. Szer, J. Liesveld, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Significant Improvements in the Practice Patterns of Adult Related Donor Care in US Transplantation Centers.

M. Norkin, J. Liesveld, Z. DeFilipp, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

P. Hari, W. Tse, M. Horowitz, 2018, Haematologica.

Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity.

D. Marin, E. Shpall, B. Andersson, 2020, Blood advances.

Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion.

D. Marin, E. Shpall, B. Andersson, 2018, Blood.

Acute rhabdomyolysis after concurrent administration of interleukin‐2, interferon‐alfa, and chemotherapy for metastatic melanoma

A. Buzaid, S. Legha, P. Anderlini, 1995, Cancer.

Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease.

F. Turturro, L. Medeiros, U. Popat, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival.

B. Andersson, M. Keating, R. Champlin, 2004, Experimental hematology.

fludarabine, cyclophosphamide, and rituximab relapsed follicular lymphoma after nonmyeloablative conditioning with Eight-year experience with allogeneic stem cell transplantation for

P. Mclaughlin, N. Ueno, L. Kwak, 2013 .

Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy.

H. Kantarjian, F. Cabanillas, M. Albitar, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results.

D. Marin, K. Young, E. Jabbour, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen

N. Ueno, B. Andersson, A. Younes, 2005, Bone Marrow Transplantation.

Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results.

W. Erwin, H. Macapinlac, L. Medeiros, 2012, Blood.

High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma

D. Couriel, R. Champlin, J. Mcmannis, 2006, Leukemia & lymphoma.

Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation

P. Thall, R. Başar, K. Rezvani, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s lymphoma: the updated M.D. Anderson Cancer Center experience

M. Munsell, N. Ueno, B. Andersson, 2008, Haematologica.

Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis

K. Rezvani, S. Parmar, E. Shpall, 2021, Haematologica.

Can we cure refractory Hodgkin’s lymphoma with transplantation?

U. Popat, L. Fayad, R. Champlin, 2020, Bone Marrow Transplantation.

Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation.

R. Champlin, S. Giralt, P. Anderlini, 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Optimizing the Conditioning Regimen for HCT in Myelofibrosis: Long-term Results of a Prospective Phase II Clinical Trial.

E. Shpall, S. Verstovsek, B. Andersson, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation

H. Deeg, J. Kurtzberg, M. Ayas, 2014, Haematologica.

High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age.

U. Popat, M. Qazilbash, D. Couriel, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD.

E. Jabbour, F. Turturro, U. Popat, 2014, Blood.

Results of a Phase I/II Study of Gemtuzumab Ozogamicin Added to Fludarabine (F), Melphalan (M) and Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed Myeloid Leukemias.

E. Shpall, S. Kornblau, M. Qazilbash, 2005 .

Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival.

J. Kanda, R. Gale, J. Pidala, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Just‐in‐time rescue plerixafor in combination with chemotherapy and granulocyte‐colony stimulating factor for peripheral blood progenitor cell mobilization

Y. Nieto, U. Popat, M. Qazilbash, 2013, American journal of hematology.

Cytarabine, Ki‐67, and SOX11 in patients with mantle cell lymphoma receiving rituximab‐containing autologous stem cell transplantation during first remission

L. Medeiros, C. Bueso-Ramos, U. Popat, 2013, Cancer.

HLA-mismatched bone marrow transplantation in severe aplastic anemia

U. Popat, M. Shah, P. Anderlini, 2017, Bone Marrow Transplantation.

26 Reduced early transplant-related mortality following allogeneic stem cell transplantation (SCT) with fludarabine-based, reduced-intensity conditioning from matched related and unrelated donors in advanced Hodgkin's disease (HD)

N. Ueno, B. Andersson, D. Couriel, 2003 .

Program cells: results of a prospective trial from the National Marrow Donor Adverse events among 2408 unrelated donors of peripheral blood stem

B. Logan, S. Leitman, A. Pulsipher, 2012 .

Delayed effects of rhG-CSF mobilization treatment and apheresis on circulating CD34+ and CD34+ Thy-1dim CD38- progenitor cells, and lymphoid subsets in normal stem cell donors for allogeneic transplantation.

B. Andersson, P. Anderlini, M. Körbling, 1996, Bone marrow transplantation.

Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant

D. Marin, E. Jabbour, L. Medeiros, 2021, Clinical Cancer Research.

Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation

N. Ueno, R. Champlin, P. Anderlini, 2013, Journal of Cancer.

High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy

T. Buchholz, M. Cristofanilli, P. Anderlini, 2006, Bone Marrow Transplantation.

A randomized phase II study of standard‐dose versus high‐dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B‐cell non‐hodgkin lymphomas: long term results

E. Shpall, Shaoying Li, Y. Nieto, 2017, British journal of haematology.

Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma.

E. Shpall, B. Andersson, Y. Nieto, 2021, Transplantation and cellular therapy.

Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement

C. Flowers, E. Shpall, Y. Nieto, 2022, Blood advances.

Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma

W. Erwin, H. Macapinlac, K. Young, 2018, Clinical Cancer Research.

Gemcitabine, Busulfan and Melphalan (GemBuMel) Is a New High-Dose Chemotherapy (HDC) Regimen with High Activity In Refractory Hodgkin's Lymphoma (HL) Patients Receiving An Autologous Stem-Cell Transplant (ASCT): A Contemporaneous Comparison with BEAM and Busulfan/Melphalan (BuMel)

S. Parmar, E. Shpall, B. Andersson, 2010 .

Nonmyeloablative Allogeneic Transplantation in the Imatinib Era: Three Chances To Achieve Molecular Remission in CML.

E. Shpall, M. Qazilbash, R. Champlin, 2007 .

Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.

P. Thall, Y. Oki, E. Shpall, 2018, Biology of Blood and Marrow Transplantation.

Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft Versus Host Disease

K. Rezvani, D. Marin, E. Shpall, 2020 .

A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma.

Michael L. Wang, P. Thall, U. Popat, 2008 .

Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients.

P. Thall, B. Andersson, K. van Besien, 1997, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Myeloablative Timed Sequential Busulfan is Safe and Appears Promising in Older Patients with AML/MDS

D. Marin, S. Parmar, E. Shpall, 2016 .

Practice Patterns for Evaluation, Consent and Care of Related Donors and Recipients At Hematopoietic Stem Cell Transplant Centers in the United States: Is Conflict-of-Interest an Unrecognized Issue?

D. Stroncek, M. Pulsipher, S. Leitman, 2009 .

Zevalin®/BEAM/Rituximab vs BEAM/Rituximab and Autologous Stem Cell Transplantation (ASCT) for Relapsed Chemosensitive Diffuse Large B-Cell Lymphoma (DLBCL): Impact of the IPI and PET Status.

Michael L. Wang, D. Podoloff, P. Mclaughlin, 2007 .

Pentostatin, Tacrolimus, and “Mini”-Methotrexate for Graft-Versus-Host Disease (GVHD) Prophylaxis: A Phase I/II Controlled, Randomized Study.

E. Shpall, M. Munsell, S. Kornblau, 2004 .

Bfr (bendamustine, fludarabine, rituximab) Vs. FCR Nonmyeloablative Allogeneic Conditioning In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Outcome Results Including Minimal Residual Disease Analysis

E. Jabbour, U. Popat, Q. Bashir, 2013 .

Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning: A Novel Regimen Inducing Immunosuppression Without Myelosuppression

E. Jabbour, F. Turturro, U. Popat, 2013 .

Efficacy and Safety of Yttrium 90 (90Y) Ibritumomab Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed Non-Hodgkin’s Lymphoma (NHL).

D. Podoloff, P. Mclaughlin, N. Ueno, 2006 .

A Long-Term Survivor of Disseminated Aspergillus and Mucorales Infection: An Instructive Case

G. Fuller, D. Kontoyiannis, P. Anderlini, 2014, Mycopathologia.

Myelofibrosis and Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RISCT).

E. Shpall, B. Andersson, Y. Nieto, 2007 .

Harnessing graft‐versus‐malignancy: non‐myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy

N. Ueno, S. Kornblau, R. Champlin, 2000 .

Reduced Severe aGVHD and Improved Survival Using Post Transplant Cyclophosphamide/Tacrolimus/Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receiving Myeloablative Fractionated Busulfan Conditioning Regimen

K. Rezvani, D. Marin, E. Shpall, 2019, Blood.

Treatment of acute myelogenous leukemia.

E. Estey, F. Mandelli, R. Zittoun, 1995 .

H. Macapinlac, U. Popat, M. Qazilbash, 2008, British Journal of Haematology.

Peripheral-blood stem cells versus bone marrow from unrelated donors.

P. Westervelt, S. Mineishi, D. Porter, 2012, The New England journal of medicine.

Haploidentical Transplantation For Patients With Advanced Hematologic Malignancies With Melphalan-Based Conditioning – Interim Results From a Phase II Clinical Trial

M. Konopleva, S. Parmar, E. Shpall, 2013 .

J. Wingard, B. Shaw, H. Lazarus, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation.

N. Ueno, K. Cleary, B. Andersson, 1999, Blood.

Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program.

J. Wingard, D. Stroncek, B. Shaw, 2013, Blood.

Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma.

L. Medeiros, C. Tam, U. Popat, 2009, Blood.

Conditioning regimens Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen

N. Ueno, B. Andersson, L. Fayad, 2005 .

Clinical outcomes in adult patients with aplastic anemia: A single institution experience

S. Parmar, H. Kantarjian, G. Garcia-Manero, 2017, American journal of hematology.

Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow allografts have improved Long-term Overall and Graft-versus-Host Disease, Relapse-Free Survival Biol Blood Marrow Transplant.

J. Kanda, J. Pidala, M. Boyiadzis, 2019 .

Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study.

D. Berry, S. Parmar, M. Munsell, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of Donor Type and Melphalan Dose on Allogeneic Transplant Outcomes for Patients with Lymphoma

S. Parmar, Y. Nieto, U. Popat, 2021 .

Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30(+) Lymphoma Patients Who Received Multiple Prior Lines of Treatment.

Y. Nieto, U. Popat, S. Gerson, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.